No, It's Not Just Out-Of-Pocket Costs That Are A Problem, John Arnold Tells Pharma
Executive Summary
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.
You may also be interested in...
Arnold Foundation Will Retain Drug Pricing Focus As Health Care Agenda Grows
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.
US Drug Pricing Reforms Testing Limits Of Executive Action
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.